What is Protego Biopharma?
Protego Biopharma operates at the intersection of advanced molecular biology and therapeutic innovation. The company is dedicated to the discovery and development of first-in-class small molecule therapeutics designed to rectify protein misfolding, a root cause of numerous chronic degenerative conditions. By leveraging a data-driven methodology, Protego focuses on restoring protein stability and enhancing cellular homeostasis. Their market position is defined by a commitment to addressing unmet medical needs in areas such as myopathy and cardiomyopathy, where traditional treatment modalities have historically struggled to provide effective, long-term solutions for patients.
How much funding has Protego Biopharma raised?
Protego Biopharma has raised a total of $51M across 1 funding round:
Series A
$51M
Series A (2021): $51M with participation from Lightspeed Venture Partners, Vida Ventures, and MPM BioImpact
Key Investors in Protego Biopharma
Lightspeed Venture Partners
A global multistage venture capital firm that partners with founders from seed through IPO, focusing on technology and infrastructure sectors.
Vida Ventures
A life sciences investment firm founded by scientists and entrepreneurs dedicated to advancing transformative biomedical innovations.
MPM BioImpact
An investment firm that manages early-stage and impact funds, specifically focused on converting scientific research into viable clinical therapeutics.
What's next for Protego Biopharma?
With the recent influx of capital, Protego Biopharma is poised to scale its drug discovery infrastructure and expand its translational research capabilities. The strategic roadmap involves deepening the validation of its pharmacological chaperone platform to address a broader spectrum of degenerative diseases. By prioritizing the optimization of its lead candidates, the company aims to reach critical clinical milestones that will further solidify its standing in the competitive biotech landscape. Future growth will likely be characterized by increased collaboration with academic institutions and potential partnerships with larger pharmaceutical entities to facilitate the commercialization of its therapeutic pipeline.
See full Protego Biopharma company page
